Published 3 months ago

Iktos acquires Synsight, a life sciences technology company specializing in protein-protein and RNA-protein interactions-targeted drug discovery

Summary by Benzinga

PRESS RELEASE Iktos acquires Synsight, a life sciences technology company specializing in protein-protein and RNA-protein interactions-targeted drug discovery Synsight provides Iktos with an exclusive worldwide license to INSERM's patented technology enabling high performance AI-driven in cellulo screening of modulators of protein-protein and RNA-protein interactions The merger further complements Iktos' AI-based drug discovery platform, that c…

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center1Last Updated3 months agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Iktos acquires Synsight, a life sciences technology company specializing in protein-protein and RNA-protein interactions-targeted drug discovery

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics